Clinical Efficacy of Decitabine Combined with Modified CAG Regimen for Relapse/Refractory Acute Myeloid Leukemia with AML1-ETO

Abstract

To investigate the clinical characteristics of patients with relapse-refractory acute myeloid leukemia(AML) with AML1-ETO+, and therapeutic effcacy and side effects of decitabine combined with modified CAG regimen. Clinical data of 8 cases of AML with AML1-ETO+ from June 2015 to January 2016 were analyzed retrospectively, including age, sex, initial symptoms, peripheral blood and bone marrow characteristics and so on. at the same time, the therapeutic effcacy and side effects of decitabine combined with modified CAG regimen were evaluated. The 8 patient were with median age of 44.5(16-59) years. Among these 8 patients, 1 patients were relapsed and other 7 patients were relapse/refractory patients, their median white blood cell count was 23.57(7.5-65.29)×109/L, median platelet count was 40(19-69)×109/L, median hemoglobin 1evel was 107(79-131) g/L, median lactate dehydrogenase level was 313.5(124.1-865.9) U/L at the initial diagnosis. The results showed that after treatment with decitabine combined with modified CAG, 7 patients achieved complete remission, 1 patient did not achieve remission, the overall remission rate was 87.5%(7/8). The main side effects of this regimen was myelosupp-ression, there were no new lung infection and other serious complications, 1 case without complete remission was treated with FLAG, and died of heart failure. According to preliminary results of decitabine combined with modified CAG regimen for treatment of relapse/refractory AML patients with AMLl-ETO+ displays higer remission rate and lower side effects.